

RAID-CRC



The Problem

Colonoscopy, the gold standard for CRC diagnosis, is expensive and hazardous

Existing non-invasive tools for CRC screening, such as the fecal immunochemical test (FIT), have low sensitivity and reduced predictability, leading to a high rate of false positive results and a large number of unnecessary colonoscopies.

The Solution

Faster, reliable and cheaper medical diagnosis for CRC
RAID-CRC (Risk Assessment Intestinal Disease for Colorectal Cancer) is a patented, non-invasive tool for CRC screening that allows CRC early detection in just 2h and with a cost non exceeding 12€ per sample.

The Product

RAID-CRC is the first non-invasive technology for CRC screening based on detecting a specific **bacterial signature** in the fecal sample. This tool allows **reliable** and **fast** CRC **early** detection, increasing sensitivity for precancerous lesions to **59%**, and reducing up to **32%** of unnecessary colonoscopies.



Milestones

Founded
2014

Proof of Concept
2015
PCT Application

Analytic Validation
2016

Patent protection
2017

Clinical Validation
2018

CE Mark/Market Launch
2019-2020

Key Metrics

€10 Price/kit

80% Potential Penetration Rate

€500,000 Projected Gross
Annual Revenue in 2018

€2.3 Billion/yr Potential Market

150% Sales Increase for the
RAID-CRC test in 2019

4M€ Current Valuation in the
Market


Potential Market

World Population aged 50-75: 1.5 Billion <https://esa.un.org/>


Spain 33.7%

Europe 33.1%

World 22.1%



Funding Goals



Founders

CEO
Mariona Serra



Medical Director
Xavier Aldeguer



CRO
Jesús García-Gil



Strategic Advisor
Jaume Amat

